Adjuvant atezolizumab in Japanese patients with resected stage <scp>IB‐IIIA</scp> non‐small cell lung cancer (<scp>IMpower010</scp>)
Hirotsugu Kenmotsu(Shizuoka Cancer Center), Haruka Nagao(Chugai Pharma (United States)), Haruhiro Saito(Kanagawa Cancer Center), Shizuka Nakagawa(Chugai Pharma (United States)), Wataru Nishio(Kobe University), Shunichi Sugawara(Sendai Kousei Hospital), Yuichiro Ohe(National Cancer Center), Morihito Okada(Hiroshima University), Yasutaka Watanabe(Saitama Cancer Center), Toyofumi F. Chen‐Yoshikawa(Nagoya University)
Cited by 20
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835